国际肝癌协会(ILCA)关于肝细胞癌风险分层与监测的白皮书
国际肝癌协会(ILCA)于2022年6月召开肝细胞癌风险分层与监测专题研讨会,形成本白皮书。文章总结肝细胞癌监测领域的现状、正在开展的研究以及新兴策略转化所面临的障碍,涉及风险分层算法、生物标志物、提高监测依从性的干预措施以及新型影像和血液监测检测。
要点
- 肝细胞癌监测旨在早期发现肿瘤、促进治愈性治疗并降低癌症相关死亡率。
- 慢性乙型肝炎病毒感染者的监测有大型随机对照试验支持,肝硬化患者有多项队列研究支持。
- 风险分层不充分、监测使用不足和筛查试验准确性欠佳是临床实践中的主要障碍。
核心结论
- 需要数据来确立新兴监测策略的临床效用,即提高早期肿瘤检出率和降低肝细胞癌相关死亡率。
- 若成功,这些数据可能促成精准筛查模式,将监测策略按个体肝细胞癌风险量身定制以最大化总体监测价值。
- 设计和实施这些验证工作时必须考虑实际和后勤方面的因素。
研究设计与样本
- 国际肝癌协会(ILCA)于2022年6月召开肝细胞癌风险分层与监测专题研讨会,本文为基于该研讨会的白皮书。
主要发现
- 慢性乙型肝炎病毒感染者的肝细胞癌监测由一项大型随机对照试验支持,肝硬化患者由多项队列研究支持。
- 临床实践中的监测有效性受风险分层不充分、监测使用不足和筛查试验准确性欠佳等障碍限制。
- 已提出风险分层算法和生物标志物以更好识别高危个体、干预措施以提高监测依从性,以及新兴的影像和血液监测检测以提高早期肝细胞癌检出的敏感性和特异性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major research efforts in liver cancer have been devoted to increasing the efficacy and effectiveness of surveillance for hepatocellular carcinoma (HCC). As with other cancers, surveillance programmes aim to detect tumours at an early stage, facilitate curative-intent treatment, and reduce cancer-related mortality. HCC surveillance is supported by a large randomised-controlled trial in patients with chronic HBV infection and several cohort studies in cirrhosis; however, effectiveness in clinical practice is limited by several barriers, including inadequate risk stratification, underuse of surveillance, and suboptimal accuracy of screening tests. There are several proposed strategies to address these limitations, including risk stratification algorithms and biomarkers to better identity at-risk individuals, interventions to increase surveillance, and emerging imaging- and blood-based surveillance tests with improved sensitivity and specificity for early HCC detection. Beyond clinical validation, data are needed to establish clinical utility, i.e. increased early tumour detection and reduced HCC-related mortality. If successful, these data could facilitate a precision screening paradigm in which surveillance strategies are tailored to individual HCC risk to maximise overall surveillance value. However, practical and logistical considerations must be considered when designing and implementing these validation efforts. To address these issues, ILCA (the International Liver Cancer Association) adjourned a single topic workshop on HCC risk stratification and surveillance in June 2022. Herein, we present a white paper on these topics, including the status of the field, ongoing research efforts, and barriers to the translation of emerging strategies.
引用
- Singal AG, Sanduzzi-Zamparelli M, Nahon P, et al. International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance. J Hepatol. 2023. PMID: 36854345. doi:10.1016/j.jhep.2023.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。